News Pfizer's Tukysa greenlit for earlier use in breast cancer Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
News Rhapsido is first drug cleared for chronic hives disorder SD Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
News Click claims FDA okay for first-in-class schizophrenia DTx Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
News Lilly's BTK drug Jaypirca joins first-line options in US Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?
News FDA clears first drug for MCT8 deficiency Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.
News AbbVie's Cerevel takeover delivers Parkinson's approval The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.